Skip to content

Treatment of Port Wine Stains in Children With Pulsed Dye Laser and Timolol Gel

Treatment of Port Wine Stains in Children With Pulsed Dye Laser and Timolol Gel

Status
Terminated
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01272609
Enrollment
25
Registered
2011-01-10
Start date
2011-02-16
Completion date
2012-09-24
Last updated
2026-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melanoma

Brief summary

Pulsed dye laser (PDL)is the gold standard treatment of port wine stains (PWS). However, many sessions are required and failure or relapses are not uncommon. It has been demonstrated that a neoangiogenesis occurs after PDL, explaining at least partially those failure. The objective of this study is to evaluate the use of a topical beta-blocker (timolol 1% gel) as a combination treatment with PDL for treating PWS. Methods. Prospective multicenter study comparing PDL alone to PDL + timolol. Sessions of PDL will be performed once a month for 3 months. One group will be treated with PDL alone and the other will also applied timolol 1% gel twice a day during treatment. The evaluation will be done one month after the third session.

Interventions

DRUGTimolol + LCP

Three sessions of LCP in 595nm (diameter of spot 7mm; duration of shooting 1,5ms; Fluence 8 J / cm ² if LCP of Candela © or 7 J / cm ² if LCP of Cynosure ©) spaced out of 1 month. Twice-daily applications on the zone treated by the LCP of timolol frost and will be begun that very evening by the first session and will be pursued 15j after the 3rd session of LCP. The maximum surface of treatment will be 100 cms ².

DEVICELCP

Three sessions of LCP in 595nm (diameter of spot 7mm; duration of shooting 1,5ms; Fluence 8 J / cm ²if LCP of Candela © or 7 J / cm ²if LCP of Cynosure © spaced out of 1 month.

Sponsors

Centre Hospitalier Universitaire de Nice
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
6 Months to 18 Years
Healthy volunteers
No

Inclusion criteria

* Children from 6 months to 18 year-old. * PWS of the face * No prior treatement with PDL * Membership or beneficiary of a national insurance scheme. * Consent signed by the parents and by the patient if he is old enough to understand

Exclusion criteria

* Child with whom the angioma plan was already handled by laser or pulsed lamp * Histories of asthma or obstructive bronchitis * severe allergic Rhinitis and hyper bronchial ability to react * Bradycardie sinusale, block auriculo-ventriculaires of the second or third degree * unchecked Cardiac insufficiency * cardiogenic Shock * untreated Phéochromocytome * Sentimentality in the timolol or in one of these excipients, and\\or in the other bétabloquants * Taken by floctafénine or by sultopride * Taken of bétabloquants by oral route, of inhibitors calcic or of amiodarone * severe peripheral circulatory Disorders(Confusions of Raynaud) * arterial Low blood pressure * Pregnancy and feeding * Absence of effective contraception at the girls old enough to procreate * Contraindication in the use of cream with lidocaïne and with prilocaïne

Design outcomes

Primary

MeasureTime frameDescription
IGAone month after the third session* IGA (investigator global assessment) at 3 or 4 marked improvement or complete clearance one month after the third session. Blinded evaluation by two physicians on standardized photos * Colorimetric analysis

Secondary

MeasureTime frameDescription
Subjective evaluation of the patients on visual analogical scalethree monthsSubjective evaluation of the patients on visual analogical scale

Countries

France

Contacts

PRINCIPAL_INVESTIGATORPASSERON Thierry, Pu-Ph

CHU de Nice - Service de Dermatologie - Hôpital de l'Archet - 151 Route de saint-antoine de ginestière 06200 Nice

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 18, 2026